Persistent Inflammation After Anti-Tubercular Therapy in Tubercular Serpiginous-Like Choroiditis: A Multivariate and Network-Based Risk Analysis
Translational Vision Science & Technology · 2025
DOI: 10.1167/tvst.14.12.27 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2025. Verfasst von Natasha Kesav und 6 weiteren Autor:innen. Beteiligte Einrichtung: Saroja A Rao Center for Uveitis, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, India. Hauptthemen laut MEDLINE: Choroiditis, Antitubercular Agents, Tuberculosis, Ocular, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Purpose
Antitubercular therapy (ATT) for tubercular serpiginous-like choroiditis (TB-SLC) is well-established, but not infallible. In this study, we investigated the risk factors underlying persistent inflammation after ATT in TB-SLC patients.
Methods
We retrospectively reviewed consecutive TB-SLC patients, who completed ≥6 months of ATT. The primary outcome measure was persistent inflammation at the completion of ATT. The risk factors for persistent inflammation were analyzed using multivariate logistic regression. Additionally, a categorical network analysis was performed to explore the relationships among key clinical variables. The anti-inflammatory therapy was quantified as total immunosuppressive load (TIL) by scoring systemic and local corticosteroid treatments.
Results
Sixty-five patients, 71% (n = 46) males, with a median age of 33 ± 11.1 years, 45% (n = 29) bilateral, were included. Twelve patients (18.5%; 17 eyes [18.1%]) had ongoing inflammation at the conclusion of ATT. In multivariate regression analysis, the mean TIL at month 1 (adjusted odds ratio, 0.64; 95% confidence interval, 0.43-0.97; P = 0.04) and persistent inflammation at month 3 of ATT (adjusted odds ratio, 13.44; 95% confidence interval, 1.61-111.92; P = 0.02) were risk factors for persistent inflammation after ATT. Network analysis revealed strong mutual associations among low 1-month TIL, persistence at 3 months, paradoxical worsening, and 6-month ATT duration.
Conclusions
Initial immunosuppression offers protection, and ongoing inflammation during therapy increases the risk of persistent inflammation after ATT. Paradoxical worsening and shorter ATT duration may affect these risk factors. Translational Relevance: Persistent inflammation after antitubercular therapy for tubercular serpiginous-like choroiditis is mainly determined by nonmicrobial factors, most notably the level of immunosuppression at the start of antitubercular therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Saroja A Rao Center for Uveitis, LV Prasad Eye Institute, Kallam Anji Reddy Campus, Hyderabad, India.
- Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.
- Clinical Epidemiology and Biostatistics, LV Prasad Eye Institute, Hyderabad, India.
- ABO Eye Institute, Nagpur, India.
- Anant Bajaj Retina Institute, LV Prasad Eye Institute, Hyderabad, India.
Förderung
- Wellcome Trust
Zitieren
APA
Kesav, N., Nasir, S., Ali, M. H., Sawal, R. T., Narula, R., Tyagi, M., & Basu, S. (2025). Persistent Inflammation After Anti-Tubercular Therapy in Tubercular Serpiginous-Like Choroiditis: A Multivariate and Network-Based Risk Analysis. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.14.12.27
Vancouver
Kesav N, Nasir S, Ali MH, Sawal RT, Narula R, Tyagi M, et al. Persistent Inflammation After Anti-Tubercular Therapy in Tubercular Serpiginous-Like Choroiditis: A Multivariate and Network-Based Risk Analysis. Translational Vision Science & Technology. 2025. doi:10.1167/tvst.14.12.27
BibTeX
@article{Kesav2025,
author = {Kesav, Natasha and Nasir, Shabtab and Ali, Mohammed Hasnat and Sawal, Rashi Taori and Narula, Ritesh and Tyagi, Mudit and Basu, Soumyava},
title = {Persistent Inflammation After Anti-Tubercular Therapy in Tubercular Serpiginous-Like Choroiditis: A Multivariate and Network-Based Risk Analysis},
journal = {Translational Vision Science & Technology},
year = {2025},
doi = {10.1167/tvst.14.12.27}
}
EUVIMED